FOXD1 and neoplasm: Low plasmatic PlGF levels have been reported in PE women and it has been seen that FOXD1 mutations have led to reduced induction capacity on the PlGF promoter in recurrent pregnancy loss patients, whilst PlGF overexpression has been linked to enhanced angiogenesis in tumours (Laissue et al., 2016, Chau et al., 2017 and references therein).